Not Approved (US) Longevity & Mitochondrial

Cerluten

also known as: Lung peptide bioregulator (Khavinson), Lung cytomedine

A Khavinson lung-derived short peptide bioregulator sold in Russia as a cytomedine supplement for respiratory aging. Like the rest of the Khavinson short-peptide family, supporting evidence is almost exclusively Russian-language and of low methodological rigor by Western standards; no independent replication, no FDA or EMA status, and no controlled clinical data.

One of roughly a dozen short peptide bioregulators extracted from bovine organ tissue in the Khavinson framework (Saint Petersburg Institute of Bioregulation and Gerontology). Cerluten is the lung-tissue-derived member of the series, marketed by Peptide Bioregulators Ltd. and other Russian suppliers as an oral capsule or tablet taken in courses for respiratory aging support. As with the broader Khavinson short-peptide literature, mechanistic claims center on putative "tissue-specific" gene-expression modulation, but the supporting literature is limited to Russian-language studies from the Khavinson group and close collaborators, with minimal independent replication.

Mechanism of action

Proposed mechanism within the Khavinson bioregulator framework: short peptides cross cell membranes, enter the nucleus, and bind regulatory DNA regions in a tissue-specific fashion to modulate transcription of aging-related genes in the source tissue (here, lung). Molecular validation of this mechanism at the level of specific target genes or transcription-factor binding is minimal and has not been independently replicated outside the Khavinson group. Mechanism should be regarded as speculative.

Primary uses

  • Respiratory aging support (Russian nutraceutical positioning)
  • Post-pulmonary-illness recovery (Russian clinical use)

Typical dosing

1–2 capsules 1–2 times daily in 20–30 day courses (oral)

Russian nutraceutical dosing; no human pharmacokinetic or controlled clinical data support this regimen as efficacious. Courses are typically repeated 2–4 times yearly.

Regulatory status

Not FDA- or EMA-approved. Sold in Russia and several CIS states as a nutraceutical cytomedine supplement, not as a registered medicine. Distributed by Peptide Bioregulators Ltd. (Saint Petersburg) and affiliated Khavinson-network suppliers.

References

  1. [other] Khavinson VK. "Peptides and Ageing." Neuroendocrinol Lett, 2002;23 Suppl 3:1-144 (monograph covering the full Khavinson bioregulator framework).
  2. [review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149.

Related peptides

Epithalon

A synthetic pineal tetrapeptide from the Khavinson group (St. Petersburg) — the only peptide with published data claiming telomerase activation and telomere elongation in human cell models.

Pinealon

A Khavinson tripeptide proposed to cross the blood–brain barrier and support neuronal gene expression in aging brain tissue — animal data in hypoxia and oxidative stress models; no Western clinical trials.

Endoluten

The Khavinson pineal bioregulator preparation, positioned as a "precursor/complementary" product to epithalon (the synthetic AEDG tetrapeptide). Marketed in Russia for neuroendocrine and circadian support in aging. Evidence base is Russian-language Khavinson-group studies with minimal independent replication.

Visoluten

The Khavinson retinal bioregulator preparation, marketed in Russia for age-related retinal change including macular degeneration support. Evidence base is Russian-language Khavinson-group studies. Not FDA- or EMA-approved.
Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.